Prognostic Factors in the Era of Targeted Therapies in CLL.

Prognostic Factors in the Era of Targeted Therapies in CLL.

Curr Hematol Malig Rep. 2018 Feb 23;:

Authors: Boddu P, Ferrajoli A

PURPOSE OF REVIEW: Chronic lymphocytic leukemia is heterogeneous disease characterized by a variable clinical course that is greatly influenced by various patient and disease characteristics. Over the last two decades, advent of new diagnostic methodologies has led to the identification of several factors of prognostic and predictive relevance. Furthermore, recent advances in next-generation sequencing techniques has identified recurrent novel mutations in NOTCH1, SF3B1, BIRC3, and ATM genes whose role as prognostic and predictive markers is currently being investigated. These biologic markers carry new prognostic information and their incorporation into prognostic scoring systems will likely lead to refined multi-parameter risk models.
RECENT FINDINGS: While the prognostic impact of many of the most commonly used markers on clinical outcomes in patients treated with chemo-immunotherapy is well documented, it is important to review their predictive and prognostic role in the era of novel targeted therapies. This article will discuss the currently available information on the clinical relevance of prognostic markers in patients treated with novel targeted therapies.

PMID: 29473123 [PubMed – as supplied by publisher]

Be the first to comment

Leave a Reply

Your email address will not be published.